Dana-Farber’s Belfer Institute for Applied Cancer Science and Evotec Collaborate
News May 01, 2013
The goal of the collaboration is to validate emerging epigenetic targets for oncology indications and to demonstrate the drugability of the selected target families. Evotec, Dana-Farber and Dana-Farber’s Belfer Institute for Applied Cancer Science will invest in enabling technologies, experimental target validation and the generation of chemical matter by leveraging existing expertise and platforms. The collaboration will be fuelled by substantial scientific contributions from the three organisations aligned on the objective to develop therapies that address unmet medical needs for cancer patients.
Epigenetics is a rapidly evolving high potential field of pharmaceutical research, calling for close relationships between academia and biotechnology innovators. By combining the complimentary capabilities of Dana-Farber, the Belfer Institute for Applied Cancer Science and Evotec this collaboration is uniquely positioned to succeed.
“We are very proud to have entered into this collaboration with Dana-Farber and the Belfer Institute for Applied Cancer Science, which perfectly matches our innovation strategy as described in Evotec’s Action Plan 2016”, said Dr Werner Lanthaler, CEO of Evotec. “We are enthusiastic about exploring novel targets that have the potential to produce first-in-class therapeutics for the treatment of cancer.”
Dr Jessie English, Head of Research at the Belfer Institute for Applied Cancer Science, added:”This pioneering partnership provides a unique opportunity to combine Evotec’s drug discovery capabilities with Belfer Institute for Applied Cancer Science and Dana-Farber Cancer Institute’s expertise in oncology disease biology to accelerate the development of new medicines for patients.”
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018